{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T10:37:39Z","timestamp":1785148659266,"version":"3.55.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,4]],"date-time":"2020-10-04T00:00:00Z","timestamp":1601769600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["17H04724"],"award-info":[{"award-number":["17H04724"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["18J21507"],"award-info":[{"award-number":["18J21507"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19K19409"],"award-info":[{"award-number":["19K19409"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.bbrc.2020.09.143","type":"journal-article","created":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T18:05:11Z","timestamp":1602007511000},"page":"672-678","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Inhibition of Akt\/mTOR pathway overcomes intrinsic resistance to dasatinib in triple-negative breast cancer"],"prefix":"10.1016","volume":"533","author":[{"given":"Yuya","family":"Haga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9473-8302","authenticated-orcid":false,"given":"Kazuma","family":"Higashisaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5435-5462","authenticated-orcid":false,"given":"Naoki","family":"Sekine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Tsujino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Nagano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Tsutsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2020.09.143_bib1","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1001\/jamaoncol.2016.5688","article-title":"Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study","volume":"3","author":"Global Burden of Disease Cancer","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.bbrc.2020.09.143_bib2","first-page":"87","article-title":"Global cancer statistics","volume":"65","author":"Torre","year":"2015","journal-title":"Ca - Cancer J. Clin."},{"key":"10.1016\/j.bbrc.2020.09.143_bib3","first-page":"106","article-title":"Current approaches in treatment of triple-negative breast cancer","volume":"12","author":"Wahba","year":"2015","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.bbrc.2020.09.143_bib4","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1634\/theoncologist.2011-0196","article-title":"Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer","volume":"16","author":"Li","year":"2011","journal-title":"Oncol."},{"key":"10.1016\/j.bbrc.2020.09.143_bib5","doi-asserted-by":"crossref","first-page":"6905","DOI":"10.1158\/1078-0432.CCR-11-0288","article-title":"Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study","volume":"17","author":"Finn","year":"2011","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.bbrc.2020.09.143_bib6","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1200\/JCO.2010.34.5579","article-title":"TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer","volume":"30","author":"Carey","year":"2012","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.bbrc.2020.09.143_bib7","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1200\/JCO.2011.35.7376","article-title":"First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study","volume":"30","author":"Bergh","year":"2012","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.bbrc.2020.09.143_bib8","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.bbrc.2020.09.143_bib9","doi-asserted-by":"crossref","first-page":"5533","DOI":"10.1158\/1078-0432.CCR-13-0799","article-title":"Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes","volume":"19","author":"Masuda","year":"2013","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.bbrc.2020.09.143_bib10","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/978-3-319-91439-8_2","volume":"212","author":"Lindauer","year":"2018","journal-title":"Dasatinib, Recent Results Cancer Res"},{"key":"10.1016\/j.bbrc.2020.09.143_bib11","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jss.2013.06.041","article-title":"Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells","volume":"185","author":"Kim","year":"2013","journal-title":"J.\u00a0Surg. Res."},{"key":"10.1016\/j.bbrc.2020.09.143_bib12","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1158\/0008-5472.CAN-06-3633","article-title":"Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection","volume":"67","author":"Huang","year":"2007","journal-title":"Canc. Res."},{"key":"10.1016\/j.bbrc.2020.09.143_bib13","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s10549-006-9463-x","article-title":"Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type\/\"triple-negative\" breast cancer cell lines growing in\u00a0vitro","volume":"105","author":"Finn","year":"2007","journal-title":"Breast Canc. Res. Treat."},{"key":"10.1016\/j.bbrc.2020.09.143_bib14","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41467-018-08074-0","article-title":"AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells","volume":"10","author":"Taniguchi","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbrc.2020.09.143_bib15","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1634\/theoncologist.2009-0009","article-title":"The role of Src in solid tumors","volume":"14","author":"Wheeler","year":"2009","journal-title":"Oncol."},{"key":"10.1016\/j.bbrc.2020.09.143_bib16","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.advenzreg.2006.12.018","article-title":"Stimulation of PI 3-kinase signaling via inhibition of the tumor suppressor phosphatase, PTEN","volume":"47","author":"Downes","year":"2007","journal-title":"Adv. Enzym. Regul."},{"key":"10.1016\/j.bbrc.2020.09.143_bib17","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1101\/gad.1212704","article-title":"Upstream and downstream of mTOR","volume":"18","author":"Hay","year":"2004","journal-title":"Genes Dev."},{"key":"10.1016\/j.bbrc.2020.09.143_bib18","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","article-title":"A\u00a0chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations","volume":"141","author":"Sharma","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2020.09.143_bib19","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1158\/1535-7163.MCT-08-0669","article-title":"Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma","volume":"8","author":"Milano","year":"2009","journal-title":"Mol. Canc. Therapeut."},{"key":"10.1016\/j.bbrc.2020.09.143_bib20","doi-asserted-by":"crossref","first-page":"5816","DOI":"10.1158\/1078-0432.CCR-12-1141","article-title":"Biomarkers of response to Akt inhibitor MK-2206 in breast cancer","volume":"18","author":"Sangai","year":"2012","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.bbrc.2020.09.143_bib21","first-page":"4235","article-title":"Markers for efficacy of mammalian target of rapamycin inhibitor","volume":"32","author":"Liao","year":"2012","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bbrc.2020.09.143_bib22","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1158\/0008-5472.CAN-13-3627","article-title":"Combined SFK\/mTOR inhibition prevents rapamycin-induced feedback activation of AKT and elicits efficient tumor regression","volume":"74","author":"Yori","year":"2014","journal-title":"Canc. Res."},{"key":"10.1016\/j.bbrc.2020.09.143_bib23","first-page":"1708","article-title":"Transglutaminase 2 induces intrinsic EGFR-TKI resistance in NSCLC harboring EGFR sensitive mutations","volume":"9","author":"Choi","year":"2019","journal-title":"Am J Cancer Res"}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X20319033?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X20319033?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T14:43:38Z","timestamp":1762094618000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X20319033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S0006291X20319033"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2020.09.143","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of Akt\/mTOR pathway overcomes intrinsic resistance to dasatinib in triple-negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2020.09.143","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}